Embecta Corp.
EMBC Healthcare Medical Instruments & Supplies
Embecta Corp.’s revenue for fiscal 2025 (year ended September 2025) was $1.1 billion, down 3.80% from fiscal 2024. In the quarter to June 2026, revenue fell 8.05%, EPS fell 53.9%, free cash flow fell 49.6% and total debt was flat, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow EMBC
Embecta Corp. (EMBC) EV/Sales
As of 16 October 2026, Embecta Corp. (EMBC) trades at a EV/Sales of 1.6×. Over the past ten years it has ranged from 1.3× (May 2026) to 3.0× (December 2022); the current reading is higher than 11% of that period. That is below the Medical Instruments & Supplies industry median of 2.9× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.9× | (2.02%) |
| FY2024 | 1.9× | (0.45%) |
| FY2023 | 1.9× | (26.60%) |
| FY2022 | 2.6× | 14.01% |
| FY2021 | 2.3× | 0.00% |
| FY2021 | 2.3× | 0.00% |
| FY2020 | 2.3× | 0.00% |
| FY2020 | 2.3× | 0.00% |
| FY2019 | 2.3× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1.4× | (11.64%) |
| Mar 2026 | 1.6× | (7.41%) |
| Dec 2025 | 1.7× | (6.68%) |
| Sep 2025 | 1.9× | 12.66% |
| 19 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| NNNN Anbio Biotechnology compare | n/m |
| ZJYL Jin Medical International Ltd. compare | n/m |
| OSUR OraSure Technologies, Inc. compare | 0.8× |
| ANGO AngioDynamics, Inc. compare | 1.5× |
| EMBC Embecta Corp. | 1.6× |
| PDEX Pro-Dex, Inc. compare | 2.5× |
| SMTI Sanara MedTech Inc. compare | 2.9× |
| UTMD Utah Medical Products, Inc. compare | 4.2× |
| AVR Anteris Technologies Global Corp. compare | 148× |
| Medical Instruments & Supplies industry median | 2.9× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)